Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fuquinitinib + capecitabine as maintenance therapy after first-line chemotherapy in metastatic colorectal cancer
ChiCTR2300073771Phase 4Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- May 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of fruquintinib in colorectal cancer (CRC), sponsored by Shanghai East Hospital. Primary endpoint: Progression-free survival. Planned start May 2023; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2300073771.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300073771.